Trial reportGut2002
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.
Trial report in Gut, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04680195 (Prospective, Open Clinical Trial of Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding), which is not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Open Clinical Trial of Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Pooled it
- Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.The Cochrane database of systematic reviews · 2009Pooled it
- A comprehensive review and update on acute severe lower gastrointestinal bleeding in Crohn's disease: a management algorithm.Gastroenterology report · 2024Review
- The efficacy and safety of thalidomide in the treatment of refractory Crohn's disease in adults: a double-center, double-blind, randomized-controlled trial.Gastroenterology report · 2022Article
- Identification of four key biomarkers and small molecule drugs in nasopharyngeal carcinoma by weighted gene co-expression network analysis.Bioengineered · 2021Article
- Protective Effect of Thalidomide on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis in Rats via the Inhibition of T Helper 17 Cells.Canadian journal of gastroenterology & hepatology · 2020Article
- Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients.Frontiers in medicine · 2020Article
- Thalidomide for the treatment of angiodysplasia-related recurrent gastrointestinal hemorrhage: Is low dose a safe and viable option?Clinical case reports · 2019Article
- Dually Efficacious Medicine Against Fibrosis and Cancer.Medical sciences (Basel, Switzerland) · 2019Review
- Article
- Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study.Therapeutic advances in gastroenterology · 2017Article
- Emerging biologics in inflammatory bowel disease.Journal of gastroenterology · 2017Review
- HIF-1α and HIF-2α induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide.Scientific reports · 2016Article
- Effective treatment of gastrointestinal bleeding with thalidomide--Chances and limitations.World journal of gastroenterology · 2016Review
- Herb-Partitioned Moxibustion Regulates the TLR2/NF-κB Signaling Pathway in a Rat Model of Ulcerative Colitis.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- New insights to occult gastrointestinal bleeding: From pathophysiology to therapeutics.World journal of gastrointestinal pathophysiology · 2014Review
- Inflammatory bowel disease: clinical aspects and treatments.Journal of inflammation research · 2014Review
- Thalidomide induces mucosal healing in Crohn's disease: case report.World journal of gastroenterology · 2011Article
- The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Therapeutic advances in hematology · 2011Article
- Treatment of pediatric refractory Crohn's disease with thalidomide.World journal of gastroenterology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThalidomide improves clinical symptoms in patients with therapy refractory Crohn's disease, as shown in two recent studies. The mechanism of this effect however is still unknown. Suppression of tumour necrosis factor alpha (TNF-alpha) by thalidomide has been suggested as a possible mechanism. However, effects on other cytokines have not been adequately investigated.
aimThe aim of our study was to investigate the effects of thalidomide on cytokine production in patients with inflammatory bowel disease (IBD).
methodsTen patients with therapy refractory IBD (nine Crohn's disease, one ulcerative colitis) received thalidomide 300 mg daily in a 12 week open label study. Production of TNF-alpha, interleukin (IL)-1 beta, IL-6, and IL-12 was investigated in short term cultures of stimulated colonic lamina propria mononuclear cells (LPMC) and peripheral blood monocytes (PBMC) before and after 12 weeks of treatment. LPMC were also cultured with graded doses of thalidomide.
resultsThree patients discontinued treatment because of sedative side effects. In the other patients, disease activity decreased significantly, with four patients achieving remission. Production of TNF-alpha and IL-12 decreased during treatment with thalidomide: LPMC (TNF-alpha: 42.3 (8.3) pg/ml v 16.4 (6.3); IL-12: 9.7 (3.3) v 5.0 (2.5); p<0.04) and PBMC (TNF-alpha: 62.8 (14.6) v 22.5 (9.2); p<0.02). Production of IL-1 beta and IL-6 did not change significantly. Culturing of LPMC with thalidomide showed a dose dependent decrease in TNF-alpha and IL-12 production.
conclusionThe clinical effects of thalidomide in Crohn's disease may be mediated by reduction of both TNF-alpha and IL-12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.